ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
Roivant Sciences
ROIV
|
$17.4M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 3 |
Immunovant
IMVT
|
$6.94M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
| 5 |
AVR
Anteris Technologies Global Corp. Common Stock
AVR
|
$4.35M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Instil Bio
TIL
$196M
| – | – |
-24,328
| Closed | -$422K |
|
227
Solid Biosciences
SLDB
$448M
| – | – |
-34,479
| Closed | -$128K |
|
228
Rallybio
RLYB
$24.1M
| – | – |
-13,400
| Closed | -$8.77K |
|
229
PTC Therapeutics
PTCT
$4.41B
| – | – |
-50,023
| Closed | -$2.55M |
|
230
Novartis
NVS
$248B
| – | – |
0
| – | – |
|
231
Neumora Therapeutics
NMRA
$283M
| – | – |
-26,108
| Closed | -$26.1K |
|
|
MREO
232
Mereo BioPharma
MREO
$275M
| – | – |
-10,000
| Closed | -$22.5K |
|
233
Lyra Therapeutics
LYRA
$11.8M
| – | – |
-533,200
| Closed | -$67.3K |
|
234
Keen Vision Acquisition Corporation Units
KVACU
| – | – |
-75,000
| Closed | -$842K |
|
235
Algonquin Power & Utilities
AQN
$4.32B
| – | – |
-20,000
| Closed | -$103K |
|